Tag: Uniqure NV

Finance

Biotech New Lows: ArQule (NASDAQ:ARQL), OvaScience Inc (NASDAQ:OVAS), Uniqure (NASDAQ:QURE), Egalet Corp (NASDAQ:EGLT)

ArQule Inc. (NASDAQ:ARQL) announced that the Company will present at the Needham 13th Annual Healthcare Conference. The presentation will be web cast and may be accessed through the investor relations section of the Company’s website http://www.arqule.com. ArQule, Inc. (NASDAQ:ARQL) stock performance was -2.92% in last session and finished the day at $1.66. Traded volume was 530,559.00million shares in the last session and the average volume … Continue reading Biotech New Lows: ArQule (NASDAQ:ARQL), OvaScience Inc (NASDAQ:OVAS), Uniqure (NASDAQ:QURE), Egalet Corp (NASDAQ:EGLT)

Colin Pettis
Finance

Biotech Gainers: Fate Therapeutics Inc (NASDAQ:FATE), ZIOPHARM Oncology (NASDAQ:ZIOP), Uniqure NV (NASDAQ:QURE), Sorrento Therapeutics (NASDAQ:SRNE)

Fate Therapeutics Inc (NASDAQ:FATE) recently issued a statement that it has enrolled it first patient for the second phase of this study. The primary aim of the PUMA study is to assess the efficacy and safety of PROHEMA in a randomized, controlled environment for patients that are under treatment for hematopoietic stem cell or HSC transplantation for hematologic malignancies. Fate Therapeutics Inc (NASDAQ:FATE) stock performance … Continue reading Biotech Gainers: Fate Therapeutics Inc (NASDAQ:FATE), ZIOPHARM Oncology (NASDAQ:ZIOP), Uniqure NV (NASDAQ:QURE), Sorrento Therapeutics (NASDAQ:SRNE)

Colin Pettis
FB Nasdaq FB Facebook
Finance

Biotech decliners: Aldeyra Therapeutics Inc (NASDAQ:ALDX), Uniqure NV (NASDAQ:QURE), Regulus Therapeutics Inc (NASDAQ:RGLS), Genetic Technologies Limited (ADR) (NASDAQ:GENE)

Aldeyra Therapeutics Inc (NASDAQ:ALDX) Director C. Boyd Clarke purchased 12,500 shares of the stock in a transaction dated Wednesday, May 7th. The stock was purchased at an average price of $8.00 per share, with a total value of $100,000.00. Following the acquisition, the director now directly owns 12,500 shares in the company, valued at approximately $100,000. Aldeyra Therapeutics Inc (NASDAQ:ALDX) stock performance was -8.31% in … Continue reading Biotech decliners: Aldeyra Therapeutics Inc (NASDAQ:ALDX), Uniqure NV (NASDAQ:QURE), Regulus Therapeutics Inc (NASDAQ:RGLS), Genetic Technologies Limited (ADR) (NASDAQ:GENE)

Colin Pettis